162012-67-1

Basic information

• Product Name: 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-
• Synonyms: 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-;N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine;4-(3-chloro-4-fiuoro-phen...;4-(3-chloro-4-fiuoro-phenylaMino)-7-fluoro-6-nitroquninazoline;N-(3-chloro-4-fluorophenyl)-N-(7-fluoro-6-nitroquinazolin-4-yl)acetaMide;(3-Chloro-4-fluorophenyl)(7-fluoro-6-nitroquinazolin-4-yl)amine;N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitro-4-quinazolinamine;Afatinib intermediate A
• CAS NO: 162012-67-1
• Molecular Formula: C₁₄H₇ClF₂N₄O₂
• Molecular Weight: 336.69
• Product Categories: API intermediates
• Mol File: 162012-67-1.mol
• Article Data: 35

Chemical Properties

• Melting Point: 242-244℃
• Boiling Point: 489℃
• Flash Point: 249℃
• Appearance: /
• Density: 1.616
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.707
• Storage Temp.: 2-8°C(protect from light)
• Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated)
• PKA: 5.07±0.70(Predicted)
• CAS DataBase Reference: 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-(162012-67-1)
• EPA Substance Registry System: 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-(162012-67-1)

Safety Data

• Hazardous Substances Data: 162012-67-1(Hazardous Substances Data)

Usage

Uses

4-(3-Chloro-4-fluorophenylamino)-7-fluoro-6-nitroquninazoline is an intermediate in the synthesis of Afatinib (A355300), an aminocrotonylamino-substituted quinazoline derivative used for treating cancer and diseases of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder.

InChI:InChI=1/C14H7ClF2N4O2/c15-9-3-7(1-2-10(9)16)20-14-8-4-13(21(22)23)11(17)5-12(8)18-6-19-14/h1-6H,(H,18,19,20)

Upstream product

• 367-21-5 3-chloro-4-fluorophenylamine 
• 77287-34-4 formamide 
• 162012-69-3 7-fluoro-6-nitro-3H-quinazolin-4-one 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 165107-97-1 N-(2-cyano-5-fluorophenyl)acetamide 
• 80517-22-2 2-amino-4-fluorobenzonitrile 
• 162012-69-3 7-fluoro-6-nitro-4-hydroxyquinazoline 
• 16499-57-3 7-fluoro-3,4-dihydroquinazolin-4-one 
• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 446-32-2 4-fluoroanthranilic acid 
• 162012-70-6 4-chloro-7-fluoro-6-nitroquinazoline 

Downstream Products

• 869199-63-3 (3-Chloro-4-fluoro-phenyl)-[7-(2,2-difluoro-ethoxy)-6-nitro-quinazolin-4-yl]-amine 
• 869199-53-1 7-(2-fluoroethoxy)-6-nitro-4-(3-chloro-4-fluoroaniline)quinazoline 
• 1363359-74-3 N-(4-(3-chloro-4-fluorophenyl))-7-((7-methyl-7-azabicyclo[2.2.1]heptan-2-yl)methoxy)quinazolin-4,6-diamine 
• 1363358-78-4 N-[4-(3-chloro-4-fluorophenylamino)-7-((7-methyl-7-azabicyclo[2.2.1]heptan-2-yl)methoxy)quinazolin-6-yl]-acrylamide 
• 1363358-85-3 (E)-N-[4-(3-chloro-4-fluoroanilino)-7-((7-methyl-7-azaspirocyclic[3.5]nonan-2-yl)methoxy)quinazolin-6-yl]-2-pentenamide 
• 1363358-87-5 N-[4-(3-chloro-4-fluorophenylamino)-7-(2-(7-methyl-7-azaspiro[3.5]nonan-2-yl)ethoxy)quinazolin-6-yl]-acrylamide 
• 1363359-56-1 7-(8-oxabicyclo[3.2.1]octan-3-yloxy)-N-(4-(3-chloro-4-fluorophenyl))quinazolin-4,6-diamine 
• 1363569-79-2 (E)-N-[7-(8-oxabicyclo[3.2.1]octan-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl]-4-bromo-2-butenamide 
• 1363569-75-8 (E)-N-[7-(8-oxabicyclo[3.2.1]octan-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl]-4-(piperidin-1-yl)-2-butenamide 
• 1363359-58-3 7-(7-oxabicyclo[2.2.1]heptan-2-yloxy)-N-(4-(3-chloro-4-fluorophenyl))quinazolin-4,6-diamine 
• 1363569-80-5 (E)-N-[7-(7-oxabicyclo[2.2.1]heptan-2-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl]-4-bromo-2-butenamide 
• 1363569-76-9 (E)-N-[7-(7-oxabicyclo[2.2.1]heptan-2-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl]-4-(piperidin-1-yl)-2-butenamide 
• 1363359-62-9 N-(4-(3-chloro-4-fluorophenyl))-7-(8-methyl-8-azabicyclo[3.2.1]octan-3-yloxy)quinazolin-4,6-diamine 
• 1363358-72-8 N-[4-(3-chloro-4-fluorophenylamino)-7-(8-methyl-8-azabicyclo[3.2.1]octan-3-yloxy)quinazolin-6-yl]-acrylamide 

Relevant articles and documents

STEFs: Activated Vinylogous Protein-Reactive Electrophiles

Reported here is the synthesis of a class of semi-oxamide vinylogous thioesters, designated STEFs, and the use of these agents as new electrophilic warheads. This work includes preparation of simple probes that contain this reactive motif as well as its installation on a more complex kinase inhibitor scaffold. A key aspect of STEFs is their reactivity towards both thiol and amine groups. Shown here is that amine conjugations in peptidic and proteinogenic samples can be facilitated by initial, fast conjugation to proximal thiol residues. Evidence that both the selectivity and the reactivity can be tuned by the structure of STEFs is provided, and given the unique ability of this functionality to conjugate by an addition-elimination mechanism, STEFs are electrophilic warheads that could find broad use in chemical biology.

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase

Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket. Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members. We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clinical stage EGFR inhibitors such as CI-1033. This cross-reactivity may have significant clinical implications.

Tyrosine kinase inhibitor and pharmaceutical application thereof

The invention relates to a tyrosine kinase inhibitor containing a quinazoline derivative in the fields of tumor treatment medicines and the like, and application of the tyrosine kinase inhibitor in treatment medicines for inhibiting and treating diseases caused by overexpression of tyrosine kinase. The active ingredient of the tyrosine kinase inhibitor is a quinazoline derivative with a structure shown in the following formula: a functional group containing XCH2 (CH2) nC = O is introduced on the basis of a quinazoline structure, and the functional group is easily combined with cysteine sulfydryl through nucleophilic reaction to form a covalent bond so that the activity of tyrosine kinase is irreversibly inhibited.

Preparation method of dcotinib

The invention discloses a preparation method of Dacomitinib. The preparation method comprises the following steps: methyl oxidation, reduction and condensation reaction. The preparation method disclosed by the invention is simple and effective in process, simple and reliable to operate, high in economic benefit and more suitable for industrial production; the prepared Dacomitinib is high in purity and high in overall yield.